



# Bharat Parenterals Limited

**Registered Office & Works:**

Vill. Haripura, Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Tele : (02667) - 251680, 251670, 99099 28332.

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

To  
The Manager,  
Listing Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001

Date: 22.05.2021

**SCRIP CODE: 541096**

Dear Sir,

**Sub.:** Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the captioned subject, we are glad to inform you that the company has received the license and authorization from Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO), New Delhi for the manufacturing and marketing of "**FAVIPIRAVIR ORAL SUSPENSION 100mg/ml**" which will be used for treatment of COVID-19 disease.

Further, the product patent has been already filed under fast track approval and **the Company is the first one in the Indian Market** receiving the license and authorization to manufacture and market "**FAVIPIRAVIR ORAL SUSPENSION 100mg/ml**".

We request you to kindly take the same on record.

Yours Faithfully,

**For BHARAT PARENTERALS LIMITED**

Mr. Bharat Desai  
Managing Director



**Corporate Office:**

Shree Avenue, 1st Floor, Above Bank of Baroda, Nr. Amit Nagar Circle, VIP Road, Karelibaug,  
Vadodara - 390 022 (Guj.) India. Ph.: 99099 84243